Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study (investigator-initiated) on the safety and pharmacokinetics of Bortezomib with combination chemotherapy in pediatric and young adult patients with refractory acute lymphocytic leukemia

Trial Profile

A phase I study (investigator-initiated) on the safety and pharmacokinetics of Bortezomib with combination chemotherapy in pediatric and young adult patients with refractory acute lymphocytic leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Hydrocortisone; Methotrexate; Prednisolone; Prednisolone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms BZM-ALL-1
  • Most Recent Events

    • 17 Dec 2015 Planned End Date changed from 31 Dec 2015 to 31 Mar 2016 as reported by University Hospital Medical Information Network - Japan record.
    • 07 Apr 2015 Planned End Date changed from 30 Jun 2015 to 31 Dec 2015 as reported by University Hospital Medical Information Network - Japan record.
    • 24 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top